Cholestech LDX supply pact with California Blue Cross may expand to other states.
This article was originally published in The Gray Sheet
CHOLESTECH LDX MONITORS INSTALLED AT 95 CALIFORNIA BLUE CROSS SITES as of Nov. 1, Cholestech says. Installation and training on the monitors has been completed at all 95 Blue Cross of California "Prudent Buyer Check Up Centers" covered under the supply deal. Until January, the preferred-provider centers will use the point-of-care LDX systems to test patients' total cholesterol and glucose levels in order to screen members for the risk of coronary heart disease and diabetes. HDL and estimated LDL tests will be added to the menu in 1996.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.